News

Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting
02 May 2023
Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio
16 Nov 2022
Kriya Appoints Curt Herberts as President and Chief Operating Officer
25 Aug 2022
Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine
16 May 2022
Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
26 Jan 2022
Kriya Therapeutics Completes Renovation of its Facility for Scalable Gene Therapy Manufacturing
28 Jul 2021
Kriya Therapeutics Completes $100 Million Series B Financing to Advance its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies
14 Jul 2021
Kriya Therapeutics Announces the Establishment of its Internal Manufacturing Facility for Process Development and Scalable cGMP Production of Gene Therapies for Prevalent Serious Diseases
04 Aug 2020
Kriya Therapeutics Announces $80 Million Series A Financing to Advance Gene Therapies for Highly Prevalent Serious Diseases
12 May 2020

Kriya was founded on a simple belief: Medicine can do more. Our Mission We’re bringing together the brightest minds to shape the future of medicine. Meet Our Experts

Disclaimer

Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.